Safety and Efficacy study of CUBICIN (daptomycin) under conditions of actual use

Study identifier:NIS-IPH-DUM-2010/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A descriptive study of the efficacy and safety of CUBICIN (Daptomycin) under conditions of actual use in the Philippines

Medical condition

Complicated Skin and Skin Structure Infections and Bacteremia including right-sided endocarditis

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

200

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Oct 2010

Estimated Primary Completion Date: 01 Oct 2013

Estimated Study Completion Date: 01 Nov 2013

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1	-

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Philippines Patient Safety Unit Clinical Study Information

+ 63 2 777 8816

[email protected]

Investigators

Principal Investigator

Milagros Tan

AstraZeneca Philippines